Innovation

Implantable Electroconvulsive Therapy

McLean Hospital
posted on 05/18/2011

Electroconvulsive therapy (ECT) is a treatment for psychiatric disorders such as depression or other neuropsychiatric disorders in which seizures are induced with electricity for therapeutic effect. In existing methods of ECT, electrodes are placed on either side of the patient’s head and electrical stimuli are delivered to the patient’s brain through the electrodes. Electrical stimuli are thus broadly applied throughout the brain, and the induced transcranial seizures can span large portions and different areas of the brain. ECT treatment can lead to several known side effects including confusion and memory loss. The present invention, intracranial electrical seizure therapy (ICEST), avoids such side effects by using an electrode implanted in the patient’s brain to deliver electrical stimulation to a more limited, focused target site. Such treatment induces a seizure that starts at the target site and spreads throughout a localized or generalized volume of the brain. The focal application of the electrical stimulation reduces the exposure of non-targeted brain areas to the applied stimulation, which in turn reduces side effects resulting from the electrical stimulation of these non-targeted areas.
Potential Commercial Uses: The seizures induced by ICEST will trigger physiological effects, such as regulation of neuron cell growth factors, axonal sprouting and neurogenesis, that will enable intervention for neuropsychiatric conditions characterized by neuron cell loss or degeneration. ICEST treatment is expected to be useful for disorders such as depressive disorder, bipolar affective disorder, schizoaffective disorder, obsessive compulsive disorder, and possibly also neurodegenerative diseases such as Parkinson’s disease or Alzheimer’s disease, while leading to fewer side effects than traditional ECT therapy.
Patent Status: McLean Hospital has filed a U.S. patent application claiming this invention.
Licenses Available: McLean Hospital is offering a worldwide exclusive license to this technology.


Innovation Details
 

File Number: MCL 3483.0 

Other Information:

Investigator(s)
M.D. Oscar Morales

Contact
David J. Glass, fax (617) 855-3745


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact the case manager at McLean Hospital for more information.

Request more info via email request more info
People

No people are currently associated with this innovation.


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

8,793 members 16,677 innovations 159 organizations

Browse

Alan Thomas, Director, UChicagoTech

"The iBridge Network has opened up new avenues for innovations at UChicagoTech. Relationships between researchers from other universities or industry can be built and strengthened, while investors can find new technologies to advance. "  read more...